To test this, we studied SRC–FAK binding in breast cancer MDA-MB-231 cells by coimmunoprecipitation after treatment with eCF506 and clinical kinase inhibitors dasatinib, bosutinib, and saracatinib. Here, PTK2 is linked to breast cancer.